Functional cure of chronic hepatitis B is not a dream
Journal Title: Journal of Clinical Hepatology - Year 2025, Vol 41, Issue 1
Abstract
Functional cure of chronic hepatitis B （CHB） is defined as HBsAg<0.05 IU/mL and serum HBV DNA<10 IU/mL for at least 24 weeks after discontinuation of antiviral therapy. This requires suppression of HBV replication and reduction of viral antigen production， as well as restoration of immune response to HBV infection. About 30% — 50% of highly selected CHB patients treated with nucleos（t）ide analogues can achieve functional cure after add-on therapy or monotherapy with pegylated interferon-α or a finite course of treatment with nucleos（t）ide analogues among patients with HBsAg<100 IU/mL. At present， clinical trials are being conducted for more than 40 types of novel anti-HBV drugs and immunomodulators. The combination of drugs that inhibit viral replication， reduce antigen burden， and restore immune response to HBV infection may be an ideal strategy to achieve the functional cure of CHB. However， further studies are needed to determine the optimal drug combination， the timing and sequence of medication， and the duration of treatment.
Authors and Affiliations
Hui ZHUANG
Keywords
Related Articles
- EP ID EP768399
- DOI 10.12449/JCH250101
- Views 9
- Downloads 0
Association between Helicobacter pylori infection and hepatitis B virus-related liver diseases
As a common infectious disease in China， chronic hepatitis B is hepatocyte injury and inflammatory necrosis due to immune response caused by hepatitis B virus （HBV）. Helicobacter pylori （Hp） is a Gram-negative helic...
How far is the functional cure of chronic hepatitis B from complete cure？
Functional cure is currently the ideal treatment endpoint for chronic hepatitis B （CHB） in China and globally. HBsAg seroclearance and HBV DNA that cannot be detected in peripheral blood for more than 24 weeks marks th...
Application of Model for End-Stage Liver Disease score in end-stage liver disease
The Model for End-Stage Liver Disease （MELD） score is currently used to prioritize liver allocation for cirrhotic patients awaiting liver transplantation in the world. With the application of MELD score in transplantat...
Risk factors for liver cancer in chronic hepatitis B patients and construction of a nomogram prediction model
[Objective] To investigate the risk factors for liver cancer in patients with chronic hepatitis B （CHB） in the Qidong Chronic Hepatitis B cohort， and to construct a nomogram model for predicting the risk of liver canc...
Hotspots and challenges in blocking the mother-to-child transmission of hepatitis B virus
Chronic hepatitis B virus （HBV） infection remains a major public health challenge in China， affecting over 70 million people and posing great challenges to the prevention and control of the disease. At present， both...